DIAMEDICA THERAPEUT. Logo
CA25253X2077
A2N9HB
DMAC

DIAMEDICA THERAPEUT.

Previsión

El precio objetivo medio de los analistas es de 7,59 € (+0,93 %). La mediana es de 7,29 € (-3,06 %).

Comprar
  6
Mantener
  0
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • DiaMedica Q2 loss in line with guidance; clinical programs make progress

    DiaMedica reported an adjusted loss of $0.19 per share in the second quarter, exactly matching consensus, and no revenue. The biotech company observed significant blood pressure effects in the late preeclampsia study, completed the first cohort in the early fetal growth restriction trial, and has recruited over 85% of patients for the ReMEDy2 stroke interim analysis. Cash and equivalents amounted to $43.5 million as of June 30, which management says should fund operations and studies through 2027, while R&D expenses rose markedly. The stock reacted positively in premarket trading; near‑term milestones include further cohort recruitment, top‑line data and steps toward a U.S. IND submission. » Más en de.investing.com


  • 1 Main Capital highlights DiaMedica Therapeutics for DM199 stroke‑recovery potential

    1 Main Capital said it holds an opportunistic position in DiaMedica Therapeutics, citing DM199, a recombinant form of tissue kallikrein‑1 (KLK1), as a promising therapy for ischemic stroke recovery. The fund noted extensive real‑world use of naturally derived KLK1 in China and positive signals from pooled and Phase 4 studies, while acknowledging those data are not FDA‑caliber and DM199 is not identical to the Chinese product. DiaMedica closed at $6.34 on July 31, 2026, with a market cap near $342 million and mixed recent returns. » Más en finance.yahoo.com


  • DiaMedica Therapeutics strengthens liquidity and reports slightly better EPS for Q4 2025

    DiaMedica Therapeutics reported Q4 2025 EPS of -$0.17, slightly above expectations, and increased cash and equivalents to $59.9 million (+35.8%). Operating cash outflow rose due to higher R&D spending, including the expansion of the ReMEDy2 study. Management expects current liquidity to fund operations through the end of 2027; the stock fell 2.21% in after-hours trading. » Más en de.investing.com


  • DiaMedica receives Health Canada approval for phase-2 study of DM199 in early-onset preeclampsia

    DiaMedica has received a 'No Objection Letter' from Health Canada to start an open-label phase-2 dose-finding study of DM199 in early-onset preeclampsia. The study, planned for 2026, will test three dose levels, administer DM199 subcutaneously every three days until delivery, and assess safety, tolerability and exploratory efficacy markers such as pulsatility index, sFlt‑1 and placental growth factor. The company plans to expand the study to the US and the UK after regulatory clearances. According to the data, DiaMedica shows high short-term liquidity; analysts have price targets between $11 and $25, while InvestingPro currently considers the stock overvalued. » Más en de.investing.com


  • DiaMedica must conduct additional non-clinical study for DM199 after FDA talks

    The FDA requires, before an IND filing for treatment of early-onset preeclampsia, a 10-day modified embryo‑fetal plus pre- and postnatal study in rabbits, with results expected by Q2 2026. DiaMedica announced it will carry out this study for its drug DM199 (Rinvecalinas‑Alfa) and said the talks provided regulatory clarity on the non-clinical data package. At the same time, an investigator-initiated phase‑2 trial in South Africa is already treating more than 30 women with late-stage preeclampsia; preliminary data show encouraging safety and efficacy signals. Analysts have lowered their earnings estimates following the news, and the stock has recently fallen. » Más en de.investing.com

En 2022, DIAMEDICA THERAPEUT. ya ha pagado 2,74 € en dividendos. El último pago fue en marzo de 2022.

Datos financieros

En el último trimestre, DIAMEDICA THERAPEUT. tuvo unos ingresos de 0 € y un beneficio neto de -9,99 M €

(EUR) septiembre de 2026
YoY
Ingresos 0 -
Beneficio bruto 0 -
Beneficio neto -9,99 M 35,94 %
EBITDA -9,97 M 36,08 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
405,69 M €
Número de acciones
53,96 M
Máximo/mínimo de 52 semanas
10,02 € - 4,78 €
Dividendos No
Beta
0,94
Ratio P/E
-10,86
Ratio PEG
1,57
Ratio P/B
15,53
Ratio P/S
0,00

Perfil de la empresa

DiaMedica Therapeutics Inc., una empresa biofarmacéutica en fase clínica, desarrolla tratamientos para enfermedades neurológicas y renales. El principal candidato a fármaco de la compañía es DM199, una proteína recombinante de calicreína-1 tisular humana, que se encuentra en el ensayo REDUX de fase 2 para el tratamiento de pacientes con enfermedad renal crónica moderada o grave causada por diabetes tipo I o tipo II; y en los ensayos REMEDY2 de fase 2/3 para el tratamiento de pacientes con ictus isquémico agudo. También desarrolla DM300, que se encuentra en fase preclínica para el tratamiento de enfermedades inflamatorias. La empresa era conocida anteriormente como DiaMedica Inc. y cambió su nombre a DiaMedica Therapeutics Inc. en diciembre de 2016. DiaMedica Therapeutics Inc. se constituyó en 2000 y tiene su sede en Minneapolis, Minnesota.

Nombre
DIAMEDICA THERAPEUT.
CEO
Dietrich John Pauls
Sede Minneapolis, mn
Estados Unidos
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
03/08/2012
Empleados 35

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
DMAC
🍪

Parqet  usa cookies. Más información